Showing results (191-200 of 768) with videos related to
Sort By:
Pageof 77
Seminars in Cutaneous Medicine and Surgery|April 4, 2018
Practical Strategies for Optimizing Management of PsoriasisJashin J Wu, April W Armstrong, Kenneth B Gordon, et al.Journal of the American Academy of Dermatology|January 16, 2013
Cutaneous manifestations of gastrointestinal disease: part IKejal R Shah, C Richard Boland, Mahir Patel, et al.Journal of Drugs in Dermatology : JDD|May 10, 2014
Analysis of body regions and components of PASI scores during adalimumab or methotrexate treatment for patients with moderate-to-severe psoriasisAlexander A Navarini, Yves Poulin, Alan Menter, et al.Pediatric Dermatology|September 20, 2020
Large inflamed facial cysts in teenagersHarry Meister, Nahla Shihab, Mark Lebwohl, et al.Proceedings (Baylor University. Medical Center)|May 6, 2021
Penile calciphylaxis with extragenital gangreneMarcus Zaayman, Annika Silfvast-Kaiser, Edgar Rodriguez, et al.Proceedings (Baylor University. Medical Center)|April 22, 2020
Diffuse dermal angiomatosis of the breastNicholas Nguyen, Annika S Silfvast-Kaiser, Jillian Frieder, et al.Archives of Dermatology|December 17, 2003
Treatment of psoriasis with alefacept: correlation of clinical improvement with reductions of memory T-cell countsKenneth B Gordon, Akshay K Vaishnaw, John O'Gorman, et al.Seminars in Cutaneous Medicine and Surgery|April 4, 2018
Treating to Target-A Realistic Goal in Psoriasis?Kenneth B Gordon, April W Armstrong, M Alan Menter, et al.Journal of Drugs in Dermatology : JDD|July 2, 2011
A bilateral comparison study of pimecrolimus cream 1% and a topical medical device cream in the treatment of patients with atopic dermatitisJason J Emer, Amylynne Frankel, Andrew Sohn, et al.Journal of Drugs in Dermatology : JDD|July 8, 2025
Tirbanibulin 1% Ointment: Clinical Trial and Real-World Evidence on Efficacy, Tolerability, Safety, and Patient-Reported OutcomesCharlotte Jeong, Leon Kircik, Mark Lebwohl, et al.Pageof 77